In last trading session, Rigel Pharmaceuticals (NASDAQ:RIGL) saw 0.21 million shares changing hands with its beta currently measuring 1.19. Company’s recent per share price level of $27.88 trading at $1.18 or 4.42% at ring of the bell on the day assigns it a market valuation of $491.11M. That closing price of RIGL’s stock is at a discount of -6.96% from its 52-week high price of $29.82 and is indicating a premium of 73.17% from its 52-week low price of $7.48. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.25 million shares which gives us an average trading volume of 198.52K if we extend that period to 3-months.
For Rigel Pharmaceuticals (RIGL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.29 in the current quarter.
Rigel Pharmaceuticals (NASDAQ:RIGL) trade information
Upright in the green during last session for gaining 4.42%, in the last five days RIGL remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $27.88 price level, adding 0.61% to its value on the day. Rigel Pharmaceuticals’s shares saw a change of 92.28% in year-to-date performance and have moved 14.69% in past 5-day. Rigel Pharmaceuticals (NASDAQ:RIGL) showed a performance of 94.42% in past 30-days. Number of shares sold short was 0.46 million shares which calculate 1.9 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 1.5 to the stock, which implies a fall of -1758.67% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 2. It follows that stock’s current price would jump 96.41% in reaching the projected high whereas dropping to the targeted low would mean a gain of 96.41% for stock’s current value.
Rigel Pharmaceuticals (RIGL) estimates and forecasts
Statistics highlight that Rigel Pharmaceuticals is scoring comparatively higher than the scores of other players of the relevant industry. The company added 197.70% of value to its shares in past 6 months, showing an annual growth rate of 112.14% while that of industry is 17.00. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 44.68% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 47.42M for the same. And 2 analysts are in estimates of company making revenue of 43.49M in the next quarter. Company posted 35.79M and 29.53M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.96% during past 5 years.
Rigel Pharmaceuticals (NASDAQ:RIGL)’s Major holders
Insiders are in possession of 2.18% of company’s total shares while institution are holding 68.06 percent of that, with stock having share float percentage of 69.58%. Investors also watch the number of corporate investors in a company very closely, which is 68.06% institutions for Rigel Pharmaceuticals that are currently holding shares of the company. BARCLAYS PLC is the top institutional holder at RIGL for having 10573.0 shares of worth $88000.0. And as of 2024-06-30, it was holding 0.006 of the company’s outstanding shares.
The second largest institutional holder is IFP ADVISORS, INC, which was holding about 1000.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.0006 of outstanding shares, having a total worth of $807.0.
